Background: Many single-nucleotide polymorphisms (SNPs) have been described as putative risk factors for melanoma.
The study was approved by the Scientific and Ethics Committee of Andreas Sygros Hospital.
Short title: SNPs and risk score in Greek melanoma cohort Abbreviations: AUC, area under the receiver-operating characteristics curve; GWAS, genome wide association study; GRS, genetic risk score; CM, cutaneous melanoma; GWS, genome wide significant; OR, odds ratio; SNP, single nucleotide polymorphism. 
Introduction
Cutaneous melanoma (CM) is a potentially lethal skin malignancy, showing a continuously increasing incidence rate in Caucasians worldwide. The development of melanoma is a complex process involving the interplay of environmental, phenotypic and genetic risk factors. The role of genetic factors in melanomagenesis has been recognized since the identification of CDKN2A (Hussussian et al., 1994; Kamb et al., 1994) and CDK4 (Puntervoll et al., 2013; Soufir et al., 1998; Zuo et al., 1996) as high penetrance susceptibility genes. Recent efforts have contributed to the discovery of an additional number of high risk genes, such as BAP1, MITF, TERT, POT1 and other shelterin complex GENES (ACD and TERF2IP) (Aoude et al., 2015; Bertolotto et al., 2011; Harbour et al., 2010; Horn et al., 2013; Robles-Espinoza et al., 2014; Shi et al., 2014; Yokoyama et al., 2011) . Genetic association studies, i.e., genome-wide association studies (GWAS) and candidate-gene studies have also revealed numerous common SNPs exerting more modest risk effects with more than 20 loci, including 5 new, that surpassed the genome wide significance threshold (i.e. p < 5x10 -8 ) for association with CM in recent GWAS (Law et al., 2015) . These studies have established the association of CM with pigmentation (MC1R, TYR and SLC45A2) and nevi-associated genes (MTAP, PLA2G6), as well as with loci potentially implicated in apoptosis (CASP8), DNA repair (PARP-1, ATM), metabolism (FTO) and more recently, telomerase length (TERT/CLPTM1L) (Barrett et al., 2011; Iles et al., 2013; Ward et al., 2012) . Most reported genetic variants have been summarized in an updated field synopsis of published genetic association studies (Antonopoulou et al., 2015; Chatzinasiou et al., 2011; ) .
This growing list of melanoma risk loci needs to be validated in large and independent datasets from other populations. In this context, the Greek population is of particular interest since it has a reportedly low incidence of melanoma compared to other European countries despite a high (Ferlay et al., 2013) . The aim of this study was to validate the extensive set of SNPs that have been previously associated with CM risk in an independent sample of melanoma patients and healthy controls from Greece. In addition, we assessed the cumulative impact of the genetic variants on melanoma risk prediction by calculating a weighted GRS and combined this GRS with non-genetic, phenotypic risk factors.
RESULTS
Demographics and phenotypic traits of the 800 patients with CM and 800 control subjects included in this study are shown in Table S1 . Fifty-five of 59 SNPs were genotyped with call rates ≥97%. One SNP deviated from Hardy-Weinberg equilibrium in the control population (rs1129038, p=1.6x10 -4 , in HERC2) and one SNP (rs149617956 in MITF) was monomorphic.
These SNPs were excluded from subsequent analyses. Fifty-three SNPs were considered in the final analysis, of which 26 were genome-wide significantly associated with CM based on the MelGene meta-analysis or from independent GWAS if they had not been included in the MelGene meta-analysis. Calculation of the linkage disequilibrium r 2 metric and conditional analyses revealed that all SNPs represent independent loci (data not shown).
The median power to detect the original effects as reported previously for the 53 SNPs based on the observed risk allele frequency in the control group was 0.455 (interquartile range 0.226 to 0.725) and the mean power was 0.495. For the 26 SNPs that were found to be GWS, the median and mean of the power estimates were 0.668 (0.380 to 0.906) and 0.634, respectively. Based on power calculation, it is expected that our study yielded 26 statistically significant associations among the 53 tested SNPs. Fifteen SNPs thereof were statistically significantly associated with CM in our study. Sixteen of the 26 robustly GWS variants were expected to be associated in our study, and 11 SNPs were indeed nominally significant (p=0.07 for probability test).
Association between putative risk SNPs and melanoma
Logistic regression analyses assuming an additive model revealed 15 SNPs with nominally significant (p<0.05) effect size estimates showing the same direction of effect as previously described (Table 1, Table S2 ). This included 10 SNPs that had been reported to be associated with CM with GWS, specifically rs16891982, rs1805007, rs401681, rs1885120, rs4636294, rs10931936, (Antonopoulou et al., 2015) as well as rs12918773, rs10739221, rs4778138, rs17119490 (Barrett et al., 2011; Bishop et al., 2009; Law et al., 2015) . Among the five new loci identified in the most recent GWAS meta-analysis (Law et al., 2015) the intergenic SNP with rs10739221 near TMEM38B, ZNF462 and RAD23B as well as the SNP with rs4778138 in OCA2 at 15q13.1 were significantly associated with CM in our dataset showing effect estimates into the same direction as in Law et al. (Law et al., 2015) (rs10739221: OR=1.209, p=0.015, rs4778138: OR=0.833, p=0 .014, Table 1 ). Figure S1 and Table S2 summarize the additive ORs of the eligible SNPs with melanoma risk in our study as well as the ORs reported in the original reference source. Overall, we observed a modest correlation of our effect size estimates and those reported previously (r 2 =0.41, p=0.038
for the previously GWS SNPs; r 2 =0.34, p=0.0130 for all 53 SNPs). The median risk allele frequency for the 53 risk alleles was 40.95% (IQR, 14.14-64.72%) in the Greek population. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  R  e  v  i  e  w  O  n  l  y   7 Compared to a set of European populations derived from the 1KG project panel the correlation of risk allele frequencies was very high (r 2 =0.97, P<0.0001) ( Figure S2 , Table S3 ).
Association between the GRS and melanoma
Risk score analyses yielded an OR=1.36 (95% CI: 1.21-1.52) per standard deviation increase of the GRS GWS (p=1.1x10 -7 ). The magnitude and the strength of the association were comparable for GRS ALL (OR = 1.39 (95% CI: 1.23-1.55, p=3.2x10 -8 ); Table S4 ). The adjusted ORs for melanoma showed a linear relationship with increasing percentiles of the GRS (trend test result for quintiles of GRS GWS : p=1.4x10 -7 , GRS ALL : p=3.2x10 -9 ) ( Figure 1 , Table S5 ). The OR for individuals in the lowest quintile was 0.73 (95% CI: 0.50-1.05) and for participants in the highest quintile 1.88 (95% CI: 1.29-2.74) compared with study participants in the middle quintile (Table S5 ).
The discriminative ability of the GRS GWS as measured by the C-statistic was 0.575 (95% CI:
0.549-0.604). When we considered traditional non-genetic risk factors only (i.e. sex, age, eye, hair and skin colour, phototype and tanning ability) the C-statistic was 0.764 (95% CI: 0.741-0.787). Upon combination of all genetic and non-genetic risk factors the C-statistic including GRS GWS increased to 0.775 (95% CI: 0.752-0.797, p for area under the receiver-operating characteristics curve (AUC) comparison=0.007). The results were similar when GRS All was considered ( Table 2 ). The root mean square error (RMSE) in the 5-fold cross-validation approach ranged from 0.453 to 0.465 for the non-genetic model. When the GRS GWS was added root mean square error ranged from 0.442 to 0.486. In both models cross-validation indicates a very good 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The age-stratified association results of the GRS and CM are summarized in Table S6 . As shown, the interaction between GRS and age was not significant (p ≥ 0.05).
DISCUSSION
We comprehensively assessed over 50 putative melanoma risk SNPs in a large and independent Greek dataset. Furthermore, we showed that the inclusion of common genetic variants in a CM prediction model leads to a modest improvement of its predictive abilities compared to a risk prediction model based on non-genetic factors only.
The selection of variants was mainly based on the MelGene field synopsis of genetic associations of melanoma, which systematically curates and meta-analyzes all published melanoma-associated variants (Antonopoulou et al., 2015) . Most of the variants that showed significant effects in our dataset pertained to genes controlling pigmentary traits. ) in the original GWAS (Amos et al., 2011; Barrett et al., 2011; Bishop et al., 2009; Brown et al., 2008; Iles et al., 2013; Macgregor et al., 2011; Teerlink et al., 2012) or subsequent meta-analysis in MelGene were replicated in our cohort at a nominal significant level.
Among the 5 newly identified genetic loci in a recent two-stage GWAS meta-analysis (Law et al., 2015) involving 15,990 cases and 26,409 controls, 1 intergenic locus at 9q31.2 (rs10739221), at the proximity of TMEM38B, ZNF462 and the nucleotide excision repair gene RAD23B, was replicated (Masutani et al., 1994) . In addition, the SNP in OCA2 at 15q13.1, a potential determinant of eye color, that was found GWS for melanoma in Law et al (Law et al., 2015) , was also replicated in our study.
Several risk prediction models for melanoma using conventional phenotypic or clinical factors have been published, in an effort to better assess individual risk and develop more targeted prevention plans (Olsen et al., 2015; Vuong et al., 2014) . Most of these prediction tools achieve modest discriminatory efficacy, yet their performance is variable upon independent validation due to poor calibration, lack of reproducible standardized assessment items, or heterogeneity in the definition of predictor variables (Olsen et al., 2015) . The discovery of multiple genetic variants that are associated with melanoma risk along with the constantly decreasing genotyping costs, have led to the development of genetic risk models with the potential advantage of identifying individuals at risk who may not be considered as so based on phenotypic characterization or exposure data. In the present study, we attempted to summarize the available genetic information by constructing a GRS using evidence from SNPs that have been associated with melanoma. We found that the risk for melanoma was associated with GRS even when adjusting for traditional risk factors, such as skin, hair and eye color. The results were similar for our primary model Previous risk models using various clinical risk factors yielded AUCs ranging from 0.62 to 0.86 (Davies et al., 2015; Vuong et al., 2014) . However, there are limited published prediction models incorporating genetic factors in CM (Cust et al., 2013; Fang et al., 2013; Penn et al., 2014; Stefanaki et al., 2013; Whiteman and Green, 2005) . Three studies focused on the effect of MC1R in melanoma prediction (Cust et al., 2013; Penn et al., 2014; Whiteman and Green, 2005) .
Whiteman and Greene found that MC1R variants substantially increased melanoma risk when present in persons of olive skin color (Whiteman and Green, 2005) . Cust et al concluded that MC1R is a better predictor than pigmentation characteristics in early-onset melanoma (Cust et al., 2013) , while Penn et al reported that the addition of MC1R genotype information to the baseline model resulted in a slight but statistically significant improvement in risk prediction, especially in nevus-prone patients (Penn et al., 2014) . In our previous study (Stefanaki et al., 2013 ) the addition of 8 SNPs with nominal significance to a clinical model did not substantially improve melanoma risk prediction. In the present study, as well as in a recently published study of a GRS based on 11 SNPs tested in 1,804 melanoma patients and 1,026 controls (Fang et al., 2013) , the discrimination ability of the conventional phenotypic risk model increased when the GRS was incorporated to this model (C-statistic reaching 0.775 in our study and 0.69 in the study by Fang et al). Although differences between the two studies with regards to study design and population do not allow for direct comparison, the association of GRS with CM risk was significant in both (Fang et al., 2013) .
Our sample represents the largest series of melanoma patients studied in Greece. We constructed our main GRS model based on established independent signals that showed genome-wide significance in previous studies, regardless of how they performed in our Greek case-control study. To this end, we avoided data overfitting by models that take in account only those variants with statistical significance in our population. In addition, we applied the checklist of the TRIPOD (Collins et al., 2015) and GRIPS (Janssens et al., 2011) statement recommendations, which aim to strengthen the transparency and homogeneity of reporting of multivariable and genetic risk prediction models among studies. Certain limitations apply to our study, with foremost the small size of our cohort. Several values concerning phenotypic characteristics, including the number of nevi, are missing due to variations in the information and questionnaires used by the participating centers. In addition, we did not include family history as a risk factor since this information was not available for the vast majority of our control samples. Risk prediction algorithms in other cancers, i.e., breast cancer suggest that the inclusion of family history in a polygenic risk score leads to further substantial improvement of the risk prediction model (Mavaddat et al., 2015; So et al., 2011) . In addition, we did not take into account possible gene-environment interactions or gene-gene interactions. Incorporating SNPs with a stronger evidence of association after fine mapping of relevant genomic regions (Barrett et al., 2015) , in combination with intermediate or high risk genes might further improve the risk stratification of the GRS. Although we tested the internal validity of our prediction models, genetic predictive models for melanoma would benefit from additional external validation testing in similar (southern European) or other populations. In conclusion, we replicated several genetic variants that confer susceptibility for melanoma in our population, confirming the polygenic nature of melanoma. We also explored the predictive capability of a GRS, which incorporated several GWS variants reported in the literature. The GRS was not superior from a phenotypic risk model, and its combination with phenotypic risk variables only slightly enhanced the discriminatory ability of our model. Based on our results, we cannot support the implementation of genetic variant profile in risk prediction models of melanoma. Independent studies in other populations will be required to adequately validate these findings.
MATERIALS AND METHODS

Study Population
The Greek sample consisted of patients with a histologically confirmed diagnosis of invasive melanoma at A. Sygros Hospital, a large referral center of melanoma and skin cancer in Athens and a collaborating oncological center (Laiko Hospital, Oncology Clinic), from 2000 to 2014.
Both centers receive the majority of melanoma patients from Athens, thus consisting a representative sample size of the Greek population. The control subjects were blood donors from a blood donation center in Athens and individuals with minor skin diseases and no history of skin malignancy, attending the outpatient service of our hospital. All subjects were above the age of 18.
Demographic variables, pigmentation traits (eye, hair, and skin color), skin phototype and tanning ability were obtained through a questionnaire that was given to the participants and clinical examination by a certified dermatologist. The study protocol was approved by the Scientific and Ethics Committee of A. Sygros Hospital; all participating individuals gave written informed consent prior to participating in the study.
SNP selection
Fifty nine variants were genotyped. Most of the SNPs (n=52) to be genotyped were selected from MelGene (www.melgene.org), a continuously updated database that collects all SNPs associated with melanoma risk (Antonopoulou et al., 2015; Athanasiadis et al., 2014; Chatzinasiou et al., 2011) . We further included in our study 7 GWAS SNPs from arecent GWAS meta-analysis, which were tested in our cohort as part of the replication phase (Law et al., 2015) . A MelGene SNP should have a p-value <0.05 and strong evidence of credibility using Venice criteria (grade A) (Ioannidis et al., 2008) or should be GWS (p<5x10 -8 ) if it had emerged from a GWA study to be included in our study. Thirteen out of the 52 variants selected from MelGene database were included in the analysis because of their strong biological correlation with important melanoma pathways, even if they did not meet the above criteria. 
DNA isolation, Genotyping and Quality control
Genomic DNA was isolated from peripheral blood using the QIAamp DNA blood mini kit (Qiagen). A total of 100ng from each DNA sample were used to genotype the selected SNPs, using the Sequenom iPLEX assay (Sequenom, Hamburg, Germany) (Gabriel et al., 2009 ). Our quality control criteria included the inclusion of SNPs with a genotype call rate of 97% or higher and no deviation from Hardy-Weinberg equilibrium (p< 8,5x10
-4 ). We also excluded participants that had available <90% of SNPs genotyped.
Statistical Analysis
The association of each SNP with CM was computed using logistic regression and assuming an additive model. Adjustment for multiple testing was conducted using Bonferroni correction for the effective number of SNPs included in the analysis (cut off: p=8.5x10 -4 ). Additionally, we estimated: a) the correlation of risk allele frequencies between the Europeans from a panel derived from the 1000 Genomes (1KG) project ("EUR" population, Phase 3 v5) and the Greek population and b) the correlation of the effect size estimates found in the Greek population with those reported previously. Minor allele frequencies from the 1KG panel were extracted from
SNiPA (Arnold et al., 2015) , a genetic variant-centered annotation browser.
Finally, we calculated Linkage Disequilibrium metrics (r 2 ) using PLINK 1.07, for SNPs located in the same locus. We considered SNPs with r 2 <0.6 as independent. For SNP pairs with r 2 ranging 
Power Calculation
The QUANTO software was used for power calculations (http://biostats.usc.edu/Quanto.html).
For every SNP, the power Gi to detect each of the described effects at a = 0.05 level given the observed risk allele frequency in the Greek sample, was calculated assuming an additive (perallele) genetic model. The sum of the power estimates corresponds to the number of variants that would be expected to replicate.
GRS calculation and melanoma risk prediction analyses
We constructed two different weighted GRS. Primary GRS was based on SNPs that have been found GWS from MelGene meta-analysis (n=11), 7 SNPs from Law et al. (Law et al, 2015) and 8
SNPs from independent GWAS that did not have sufficient datasets to be meta-analyzed in MelGene (GRS GWS ). A secondary GRS consisted of all analysed SNPs (GRS ALL ) (n=53 successfully genotyped of the 59) ( Table S2 ). The GRS represents a sum of the number of effect alleles weighted by their effect size estimates, specifically by their beta coefficients. The effect estimates were derived from the MelGene meta-analysis or independent published GWAS (Table   S2 ). Each weighted GRS was standardized per unit increase in the control population. We also assessed the performance of the predictive capability of the GRS by calculating the AUC. The AUC was calculated based on the covariates described above with and without the GRS. Bootstrapping (n=1,000) was used to calculate the p-values for the comparisons of the AUCs. In order to assess the internal validity of our predictive models we calculated the root mean square error, which error represents the differences between predicted and observed values, Finally, quantiles of the GRS were created and ORs were calculated and compared in 5 different categories using the 3 rd category as a reference. Moreover, we stratified the dataset into quartiles of age (i.e. age at onset for cases and age at examination for controls) and we calculated the OR within each age group. 
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